Innocan Pharma’s LPT-CBD Nears FDA Approval

InnoCan Pharma (TSE:INNO) has released an update.

Innocan Pharma has achieved a significant milestone with a positive reaction from the FDA for its LPT-CBD drug, potentially expediting its FDA approval process. The company’s alignment with FDA on its development plan and clinical study design for LPT-CBD is set to address the unmet needs of chronic pain sufferers, signaling a major leap in chronic pain management.

For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.